Association of Metabolic Syndrome with Development of New-onset Diabetes After Transplantation
Overview
Authors
Affiliations
Background: New-onset diabetes after transplantation (NODAT) is a major posttransplant complication associated with lower allograft and recipient survival. Our objective was to determine whether metabolic syndrome pretransplant is independently associated with NODAT development.
Methods: We recruited 640 consecutive incident nondiabetic renal transplant recipients from three academic centers between 1999 and 2004. NODAT was defined as the use of hypoglycemic medication, a random plasma glucose level more than 200 mg/dL, or two fasting glucose levels more than or equal to 126 mg/dL beyond 30 days posttransplant.
Results: Metabolic syndrome was common pretransplant (57.2%). NODAT developed in 31.4% of recipients 1 year posttransplant. Participants with metabolic syndrome were more likely to develop NODAT compared with recipients without metabolic syndrome (34.4% vs. 27.4%, P=0.057). Recipients with increasing number of positive metabolic syndrome components were more likely to develop NODAT (metabolic syndrome score prevalence at 1 year: 0 components-0.0%, 1-24.2%, 2-29.3%, 3-31.0%, 4-34.8%, and 5-73.7%, P=0.001). After adjustment for demographics, age by decade (hazard ratio [HR] 1.34 [1.20-1.50], P<0.0001), African American race (HR 1.35 [1.01-1.82], P=0.043), cumulative prednisone dosage (HR 1.18 [1.07-1.30], P=0.001), and metabolic syndrome (HR 1.34 [1.00-1.79], P=0.047) were independent predictors of development of NODAT at 1 year posttransplant. In a multivariable analysis incorporating the individual metabolic syndrome components themselves as covariates, the only pretransplant metabolic syndrome component to remain an independent predictor of NODAT was low high-density lipoprotein (hazard ratio [HR] 1.37 [1.01-1.85], P=0.042).
Conclusions: Metabolic syndrome is an independent predictor for NODAT and is a possible target for intervention to prevent NODAT. Future studies to evaluate whether modification of metabolic syndrome factors pretransplant reduces NODAT development are needed.
New Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences.
Popovic L, Bulum T Diagnostics (Basel). 2025; 15(3).
PMID: 39941214 PMC: 11816453. DOI: 10.3390/diagnostics15030284.
Alfieri C, Campioli E, Fiorina P, Orsi E, Grancini V, Regalia A Nutrients. 2024; 16(10).
PMID: 38794758 PMC: 11123789. DOI: 10.3390/nu16101520.
Association of Recipient APOL1 Kidney Risk Alleles With Kidney Transplant Outcomes.
Roy N, Morales-Alvarez M, Anis K, Goral S, Doria C, Kopp J Transplantation. 2023; 107(12):2575-2580.
PMID: 37527489 PMC: 11184510. DOI: 10.1097/TP.0000000000004742.
Bang J, Oh C, Kim Y, Kim S, Yu H, Kim C Front Endocrinol (Lausanne). 2023; 14:1197475.
PMID: 37424863 PMC: 10325682. DOI: 10.3389/fendo.2023.1197475.
Wang L, Huang J, Li Y, Shi K, Gao S, Zhao W Endocrine. 2023; 81(1):58-66.
PMID: 37148416 DOI: 10.1007/s12020-023-03374-y.